



## Rasha 123

11/08/2025 20:57:14

### Main Information

**Primary registry identifying number**

LBCTR2018090151

**Protocol number**

Rasha123

**MOH registration number**

20555/2018

**Study registered at the country of origin**

Yes

**Study registered at the country of origin: Specify****Type of registration**

Prospective

**Type of registration: Justify**

N/A

**Date of registration in national regulatory agency**

15/09/2018

**Primary sponsor**

Rasha

**Primary sponsor: Country of origin**

Lebanon

**Date of registration in primary registry**

16/04/2020

**Date of registration in national regulatory agency**

15/09/2018

**Public title**

Rasha 123

**Acronym**

RH

**Scientific title**

Rasha 123

**Acronym**

RH

**Brief summary of the study: English**

Great Job

**Brief summary of the study: Arabic**

السجل الوطني للأبحاث السريرية  
الأول من نوعه

**Health conditions/problem studied: Specify**

Heart Failure

**Interventions: Specify**

New medication

**Key inclusion and exclusion criteria: Inclusion criteria**

all adults

**Key inclusion and exclusion criteria: Gender**

Both

**Key inclusion and exclusion criteria: Specify gender****Key inclusion and exclusion criteria: Age minimum**

18

**Key inclusion and exclusion criteria: Age maximum**

75





**Key inclusion and exclusion criteria: Exclusion criteria**

less than 18

**Type of study**

Interventional

**Type of intervention**

Pharmaceutical

**Type of intervention: Specify type**

pharmaceutical with behavioral

**Trial scope**

Therapy

**Trial scope: Specify scope**

N/A

**Study design: Allocation**

Non-randomized controlled trial

**Study design: Masking**

N/A

**Study design: Control**

Uncontrolled

**Study phase**

1 to 2

**Study design: Purpose**

Treatment

**Study design: Specify purpose**

N/A

**Study design: Assignment**

Other

**Study design: Specify assignment**

single arm

**IMP has market authorization**

No

**IMP has market authorization: Specify**

USA

**Name of IMP**

In Love

**Year of authorization**

2014

**Month of authorization**

4

**Type of IMP**

Others

**Pharmaceutical class**

heart diseases

**Therapeutic indication**

to treat heart failure

**Therapeutic benefit**

increase ejection fraction

**Study model**

N/A

**Study model: Explain model**

N/A

**Study model: Specify model**

N/A

**Time perspective**

N/A

**Time perspective: Explain time perspective**

**Time perspective: Specify perspective**

N/A



N/A

**Target follow-up duration**

**Target follow-up duration: Unit**

**Number of groups/cohorts**

**Biospecimen retention**

Samples without DNA

**Biospecimen description**

DNA saliva samples

**Target sample size**

1000

**Actual enrollment target size**

1

**Date of first enrollment: Type**

Anticipated

**Date of first enrollment: Date**

20/10/2018

**Date of study closure: Type**

Anticipated

**Date of study closure: Date**

20/10/2020

**Recruitment status**

Complete

**Recruitment status: Specify**

**Date of completion**

**IPD sharing statement plan**

No

**IPD sharing statement description**

I do not want to share

**Additional data URL**

later

**Admin comments**

**Trial status**

Approved



## Secondary Identifying Numbers

Full name of issuing authority	Secondary identifying number
KSA	25325

## Sources of Monetary or Material Support

Name
King faisal hospital

## Secondary Sponsors

Name
None

## Contact for Public/Scientific Queries

Contact type	Contact full name	Address	Country	Telephone	Email	Affiliation
Public	Rasha Hamra	Beirut	Iceland	0255.0000	rasha@gmail	MOH
Scientific	Marie Ok	Beirut	Lebanon	565540000 0	marie@yahoo	MOH

## Centers/Hospitals Involved in the Study

Center/Hospital name	Name of principles investigator	Principles investigator speciality	Ethical approval
AUB	RH	Oncologist	Approved
USJ	RH	Oncologist	NA

## Ethics Review

Ethics approval obtained	Approval date	Contact name	Contact email	Contact phone
American University of Beirut Medical Center King faisal hospital	11/10/2018	RH	@gmail	565458
Makassed General Hospital	11/12/2019	RH	@yahoo	3336661



## Countries of Recruitment

No Countries

## Health Conditions or Problems Studied

Condition	Code	Keyword
heart failure	Heart failure (I50)	RF

## Interventions

Intervention	Description	Keyword
pharmaceutical and behavioral	new medication with lifestyle changes	RH and forever

## Primary Outcomes

Name	Time Points	Measure
increast EF	in 6 months	EF

## Key Secondary Outcomes

Name	Time Points	Measure
I dont have	later	Ok



## Trial Results

Summary results

Study results globally

Date of posting of results summaries

Date of first journal publication of results

Results URL link

Baseline characteristics

Participant flow

Adverse events

Outcome measures

URL to protocol files